AONN+ Conference Abstracts

The Role of the Navigator in an Augmented Intelligence (AI) Supported on Utilization of Palliative Care Services in Oncology

By Ajeet Gajra, MD; Yolaine Jeune-Smith, PhD; Amy Ellis; Kelly A. Miller, DNP, MPH; Danielle Bergman, RN; John Showalter, MD; Sibel Blau, MD

AONN+ Conference Abstracts, Survivorship, End-of-Life

November 2021 Vol 12, No 11

Timely integration of palliative care (PC) in the management of patients with advanced cancer is a quality benchmark in oncology. PC is often underutilized due to delayed identification and referral of appropriate patients.

Patient-Reported Outcomes from the Phase 3, Randomized Study of Acalabrutinib with or without Obinutuzumab versus Chlorambucil plus Obinutuzumab for Treatment-Naive Chronic Lymphocytic Leukemia (ELEVATE-TN)

By P Walker ; JP Sharman; W Jurczak; T Munir; V Banerji; S Coutre; JA Woyach; G Salles; WG Wierda; P Patel; MH Wang; U Emeribe; E Flood; JC Byrd; P Ghia

Clinical Research, AONN+ Conference Abstracts

December 2021 Vol 12, No 12

Nursing Experience in Patients with Chronic Lymphocytic Leukemia Receiving First-Line Ibrutinib: Up to 7 Years of Follow-Up from the Phase 3 RESONATE-2 Study

By Cara McGowan, NP; Jillian Settlemire, RN; Anita Szoke, MD; Gabriel Krigsfeld, PhD; Steven Coutre, MD; Paul Barr, MD

Clinical Research, AONN+ Conference Abstracts

December 2021 Vol 12, No 12

Mapping the PIK3CA-Related Overgrowth Spectrum Patient and Caregiver Journey Using a Patient-Centered Approach

By Dawn Aubel, EdD, MPH, APNc; Lara Rodríguez-Laguna, PhD; Kristen Davis, BS; Mellenee Finger; Robin Vlamis, MPH, CHES; Craig Johnson, DO

Clinical Research, AONN+ Conference Abstracts

December 2021 Vol 12, No 12

Impact of Age on Efficacy and Safety of Relugolix: A Subgroup Analysis from the Randomized, Phase 3 HERO Study versus Leuprolide in Men with Advanced Prostate Cancer

By Michael S. Cookson, MD, MMHC; Neal D. Shore, MD; Daniel J. George, MD; Hideyuki Akaza, MD; Daniel R. Saltzstein, MD; Ronald Tutrone, MD; Alberto Bossi, MD; Bruce Brown, MD; Bryan Selby, MS; Sophia Lu, PhD; Jackie Walling, MBChB, PhD; Bertrand Tombal, MD, PhD; Fred Saad, MD

Clinical Research, AONN+ Conference Abstracts

December 2021 Vol 12, No 12

Expert Guidance Based on Clinical Experience of Tepotinib Side Effect Management in Patients with NSCLC Harboring MET Exon 14 Skipping

By Terri Alexander, MSc

Clinical Research, AONN+ Conference Abstracts

December 2021 Vol 12, No 12

Expanding the Way We Screen for Cancer: A Path to a Multicancer Early Detection Test

By Tomasz M. Beer; Charles H. McDonnell, III; Lincoln Nadauld; Minetta C. Liu; Eric A. Klein; Robert Reid; Catherine R. Marinac; Karen C. Chung; Margarita Lopatin; Eric T. Fung; Deborah Schrag

Clinical Research, AONN+ Conference Abstracts

December 2021 Vol 12, No 12

Characterization of Adverse Reactions in Patients with Advanced Endometrial Cancer (aEC) Receiving Lenvatinib + Pembrolizumab (Study 309/KEYNOTE-775): Nurse Roles in Patient Education and Adverse-Reaction Management

By Giorgia Villa; Nicoletta Colombo; Melissa Zale; Min Ren; Lea Dutta; Vicky Makker; Vania Hom

Clinical Research, AONN+ Conference Abstracts

December 2021 Vol 12, No 12

Characterization and Management of Gastrointestinal and Skin Toxicities with Mobocertinib in EGFR Exon 20 Insertion+ Non–Small-Cell Lung Cancer

By Kelly Goodwin, NP

Clinical Research, AONN+ Conference Abstracts

December 2021 Vol 12, No 12

Adherence to Injectable and Oral Hormone Therapies in Advanced Prostate Cancer as Measured by Proportion of Days Covered

By Tao Jiang; Robert Dufour; Eddie Li; Janis Pruett

Clinical Research, AONN+ Conference Abstracts

December 2021 Vol 12, No 12

Page 5 of 37

2
3
4
5
6
7
8

SUBSCRIBE